Science & Enterprise subscription

Follow us on Twitter

  • A biotechnology company is sponsoring university research on light waves reacting in characteristic patterns for de… https://t.co/RG11kdD0as
    about 19 hours ago
  • New post on Science and Enterprise: Univ Lab, Company Developing Phone-Based Virus Sensor https://t.co/Yqq5wZPmqF #Science #Business
    about 19 hours ago
  • A blood test designed for low-resource field settings is shown to quickly detect and distinguish between different… https://t.co/7RCwijmW7N
    about 1 day ago
  • New post on Science and Enterprise: Quick Crispr-Based Test Detects Malaria in Blood https://t.co/LuZnLHRUYW #Science #Business
    about 1 day ago
  • Researchers in the U.K. created a bandage with enhanced human skeletal stem cells that in lab mice repairs simulate… https://t.co/1tD7FxaoRo
    about 2 days ago

Please share Science & Enterprise

Covid-19 Vaccines, Therapies – 31 August 2020

Covid-19 vaccine and therapy tracker

BioRender Covid-19 vaccine and therapy tracker. (BioRender.com)

31 Aug. 2020.  We return to our regular Monday feature on Science & Enterprise, an update on Covid-19 therapies and vaccines in development. The report is provided by BioRender, in Toronto, Ontario, a company offering illustration and graphics tools for life sciences, biotechnology, and other disciplines.

Since our last report on 17 August, activity is picking up in both vaccines and therapies for Covid-19. The number of vaccines in development increased by six to 170, while those in clinical trials also gained six, now at 47. Therapies, however, increased by more than twice those numbers, now at 379 in development and 293 in clinical trials, an increase of 15 in each case.

In addition to the summary dashboard shown above, the BioRender Covid-19 vaccine and therapy page provides details of the vaccines and therapies, as well as an activity feed showing news updates on these drugs.

The global vaccine effort received a boost today when the European Commission announced a contribution of €400 million ($US 477 million) to the COVID-19 Vaccine Global Access, or Covax, consortium of World Health Organization and not-for-profit groups. The Covax project is encouraging manufacturers and governments to ensure Covid-19 vaccines are available to lower income regions and the most vulnerable populations.

More from Science & Enterprise:

*     *     *

2 comments to Covid-19 Vaccines, Therapies – 31 August 2020